

**(19) World Intellectual Property
Organization
International Bureau**

(43) International Publication Date
04 November 2021 (04.11.2021)



WIPO | PCT


(10) International Publication Number
WO 2021/222145 A8

- (51) **International Patent Classification:**
A61K 31/49 (2006.01) *A61P 25/28* (2006.01)
A61K 31/485 (2006.01)
- (21) **International Application Number:**
PCT/US2021/029246
- (22) **International Filing Date:**
26 April 2021 (26.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/016,270 27 April 2020 (27.04.2020) US
- (71) **Applicant: AVANIR PHARMACEUTICALS INC.**
[US/US]; 30 Enterprise, Suite 200, Aliso Viejo, California
92656 (US).
- (72) **Inventor: DUBE, Sanjay;** 30 Enterprise, Suite 200, Aliso
Viejo, California 92656 (US).
- (74) **Agent: DORIGO, Andrea et al.;** Fish & Richardson P.C.,
PO Box 1022, Minneapolis, Minnesota 55440-1022 (US).

- (81) Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- (54) Title:** METHODS OF TREATING AGITATION ASSOCIATED WITH ALZHEIMER'S DISEASE

- (57) Abstract:** In some embodiments provided herein is a method of treating agitation associated with Alzheimer's disease in a subject, comprising administering to the subject therapeutically effective amounts of deuterated [d6]-dextromethorphan hydrobromide (d6-DM) and quinidine sulfate, wherein the subject is a patient that has been diagnosed as having Alzheimer's disease, wherein the method comprises determining the Cohen-Mansfield agitation inventory (CMAI) total score in the patient prior to said administration.



* Visit 4 (Day 43) stratification for the placebo arm is based on treatment response criteria followed by rerandomization (1:1:1).

Figure 1

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

30 December 2021 (30.12.2021)

(15) Information about Correction:

see Notice of 30 December 2021 (30.12.2021)